ERBB2 and metastatic neoplasm: For example, in HER2-negative metastatic tumors with positive hormone receptors, the first-line treatment involves hormone blockade combined with aromatase inhibitors or antiestrogens, often paired with a CDK 4/6 inhibitor like palbociclib.